AU3072392A - Protease vaccine against heartworm - Google Patents
Protease vaccine against heartwormInfo
- Publication number
- AU3072392A AU3072392A AU30723/92A AU3072392A AU3072392A AU 3072392 A AU3072392 A AU 3072392A AU 30723/92 A AU30723/92 A AU 30723/92A AU 3072392 A AU3072392 A AU 3072392A AU 3072392 A AU3072392 A AU 3072392A
- Authority
- AU
- Australia
- Prior art keywords
- protease
- amc
- lysate
- nematode
- excretory
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 108091005804 Peptidases Proteins 0.000 title claims description 80
- 239000004365 Protease Substances 0.000 title claims description 75
- 241000002163 Mesapamea fractilinea Species 0.000 title description 9
- 229960005486 vaccine Drugs 0.000 title description 8
- 102100037486 Reverse transcriptase/ribonuclease H Human genes 0.000 title 1
- 102000035195 Peptidases Human genes 0.000 claims description 78
- 239000006166 lysate Substances 0.000 claims description 52
- 239000000758 substrate Substances 0.000 claims description 40
- 108010006035 Metalloproteases Proteins 0.000 claims description 39
- 102000005741 Metalloproteases Human genes 0.000 claims description 38
- 238000000034 method Methods 0.000 claims description 36
- 108010005843 Cysteine Proteases Proteins 0.000 claims description 35
- 241000244206 Nematoda Species 0.000 claims description 35
- 102000005927 Cysteine Proteases Human genes 0.000 claims description 34
- 230000000694 effects Effects 0.000 claims description 30
- 208000015181 infectious disease Diseases 0.000 claims description 18
- 108091026890 Coding region Proteins 0.000 claims description 17
- 239000000463 material Substances 0.000 claims description 14
- 241001465754 Metazoa Species 0.000 claims description 13
- 239000003112 inhibitor Substances 0.000 claims description 13
- 239000000203 mixture Substances 0.000 claims description 12
- 230000014509 gene expression Effects 0.000 claims description 11
- 108020004414 DNA Proteins 0.000 claims description 9
- 238000002955 isolation Methods 0.000 claims description 9
- 208000000291 Nematode infections Diseases 0.000 claims description 6
- 230000003053 immunization Effects 0.000 claims description 6
- 238000002649 immunization Methods 0.000 claims description 5
- 230000002163 immunogen Effects 0.000 claims description 5
- 239000008194 pharmaceutical composition Substances 0.000 claims description 5
- 238000004113 cell culture Methods 0.000 claims description 4
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 4
- 230000001524 infective effect Effects 0.000 claims description 3
- 230000003248 secreting effect Effects 0.000 claims description 2
- 230000000295 complement effect Effects 0.000 claims 1
- 238000012258 culturing Methods 0.000 claims 1
- 230000002797 proteolythic effect Effects 0.000 claims 1
- 208000024891 symptom Diseases 0.000 claims 1
- 108090000623 proteins and genes Proteins 0.000 description 17
- 102000010834 Extracellular Matrix Proteins Human genes 0.000 description 12
- 108010037362 Extracellular Matrix Proteins Proteins 0.000 description 12
- 239000002299 complementary DNA Substances 0.000 description 12
- 210000002744 extracellular matrix Anatomy 0.000 description 12
- 238000002360 preparation method Methods 0.000 description 12
- 238000003556 assay Methods 0.000 description 11
- VHJLVAABSRFDPM-QWWZWVQMSA-N dithiothreitol Chemical compound SC[C@@H](O)[C@H](O)CS VHJLVAABSRFDPM-QWWZWVQMSA-N 0.000 description 11
- 239000013598 vector Substances 0.000 description 11
- UNXHWFMMPAWVPI-UHFFFAOYSA-N Erythritol Natural products OCC(O)C(O)CO UNXHWFMMPAWVPI-UHFFFAOYSA-N 0.000 description 10
- 238000004519 manufacturing process Methods 0.000 description 10
- 239000000047 product Substances 0.000 description 10
- 239000000284 extract Substances 0.000 description 9
- 230000001418 larval effect Effects 0.000 description 9
- 235000018102 proteins Nutrition 0.000 description 9
- 102000004169 proteins and genes Human genes 0.000 description 9
- 241000255925 Diptera Species 0.000 description 8
- 210000004027 cell Anatomy 0.000 description 8
- 239000002609 medium Substances 0.000 description 8
- YBYRMVIVWMBXKQ-UHFFFAOYSA-N phenylmethanesulfonyl fluoride Chemical compound FS(=O)(=O)CC1=CC=CC=C1 YBYRMVIVWMBXKQ-UHFFFAOYSA-N 0.000 description 8
- 239000000523 sample Substances 0.000 description 8
- 230000008569 process Effects 0.000 description 7
- 241000243988 Dirofilaria immitis Species 0.000 description 6
- 102000004190 Enzymes Human genes 0.000 description 6
- 108090000790 Enzymes Proteins 0.000 description 6
- 229940088598 enzyme Drugs 0.000 description 6
- 239000013604 expression vector Substances 0.000 description 6
- 244000045947 parasite Species 0.000 description 6
- 238000000746 purification Methods 0.000 description 6
- 241000894006 Bacteria Species 0.000 description 5
- 241000282472 Canis lupus familiaris Species 0.000 description 5
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 5
- 241000282412 Homo Species 0.000 description 5
- 230000015556 catabolic process Effects 0.000 description 5
- 201000010099 disease Diseases 0.000 description 5
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 5
- 238000010561 standard procedure Methods 0.000 description 5
- VGGGPCQERPFHOB-MCIONIFRSA-N Bestatin Chemical compound CC(C)C[C@H](C(O)=O)NC(=O)[C@@H](O)[C@H](N)CC1=CC=CC=C1 VGGGPCQERPFHOB-MCIONIFRSA-N 0.000 description 4
- VGGGPCQERPFHOB-UHFFFAOYSA-N Bestatin Natural products CC(C)CC(C(O)=O)NC(=O)C(O)C(N)CC1=CC=CC=C1 VGGGPCQERPFHOB-UHFFFAOYSA-N 0.000 description 4
- 102000008186 Collagen Human genes 0.000 description 4
- 108010035532 Collagen Proteins 0.000 description 4
- 102000015833 Cystatin Human genes 0.000 description 4
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 4
- 238000006243 chemical reaction Methods 0.000 description 4
- 238000010367 cloning Methods 0.000 description 4
- 229920001436 collagen Polymers 0.000 description 4
- 108050004038 cystatin Proteins 0.000 description 4
- 238000006731 degradation reaction Methods 0.000 description 4
- 238000003018 immunoassay Methods 0.000 description 4
- 238000000338 in vitro Methods 0.000 description 4
- 239000007924 injection Substances 0.000 description 4
- 238000002347 injection Methods 0.000 description 4
- 108020004999 messenger RNA Proteins 0.000 description 4
- 239000013615 primer Substances 0.000 description 4
- 238000000926 separation method Methods 0.000 description 4
- 210000001519 tissue Anatomy 0.000 description 4
- 229950009811 ubenimex Drugs 0.000 description 4
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 3
- 241000244038 Brugia malayi Species 0.000 description 3
- 108060005980 Collagenase Proteins 0.000 description 3
- 102000029816 Collagenase Human genes 0.000 description 3
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 3
- YZCKVEUIGOORGS-NJFSPNSNSA-N Tritium Chemical compound [3H] YZCKVEUIGOORGS-NJFSPNSNSA-N 0.000 description 3
- 150000001413 amino acids Chemical group 0.000 description 3
- 239000000872 buffer Substances 0.000 description 3
- 238000004587 chromatography analysis Methods 0.000 description 3
- 229960002424 collagenase Drugs 0.000 description 3
- 238000010828 elution Methods 0.000 description 3
- 210000004408 hybridoma Anatomy 0.000 description 3
- 230000007062 hydrolysis Effects 0.000 description 3
- 238000006460 hydrolysis reaction Methods 0.000 description 3
- 239000011159 matrix material Substances 0.000 description 3
- 230000002265 prevention Effects 0.000 description 3
- 239000011541 reaction mixture Substances 0.000 description 3
- 239000000243 solution Substances 0.000 description 3
- 241000894007 species Species 0.000 description 3
- 230000007704 transition Effects 0.000 description 3
- 229910052722 tritium Inorganic materials 0.000 description 3
- 101710179734 6,7-dimethyl-8-ribityllumazine synthase 2 Proteins 0.000 description 2
- 229920000936 Agarose Polymers 0.000 description 2
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 2
- 101000749287 Clitocybe nebularis Clitocypin Proteins 0.000 description 2
- 101000767029 Clitocybe nebularis Clitocypin-1 Proteins 0.000 description 2
- 241000256113 Culicidae Species 0.000 description 2
- 229940094664 Cysteine protease inhibitor Drugs 0.000 description 2
- 102000053602 DNA Human genes 0.000 description 2
- 108091092195 Intron Proteins 0.000 description 2
- 101710186609 Lipoyl synthase 2 Proteins 0.000 description 2
- 101710122908 Lipoyl synthase 2, chloroplastic Proteins 0.000 description 2
- 101710101072 Lipoyl synthase 2, mitochondrial Proteins 0.000 description 2
- 102000000422 Matrix Metalloproteinase 3 Human genes 0.000 description 2
- 108091034117 Oligonucleotide Proteins 0.000 description 2
- 108010076504 Protein Sorting Signals Proteins 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- DGEZNRSVGBDHLK-UHFFFAOYSA-N [1,10]phenanthroline Chemical compound C1=CN=C2C3=NC=CC=C3C=CC2=C1 DGEZNRSVGBDHLK-UHFFFAOYSA-N 0.000 description 2
- JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 description 2
- 238000001042 affinity chromatography Methods 0.000 description 2
- 238000004458 analytical method Methods 0.000 description 2
- 239000000427 antigen Substances 0.000 description 2
- 102000036639 antigens Human genes 0.000 description 2
- 108091007433 antigens Proteins 0.000 description 2
- 238000013459 approach Methods 0.000 description 2
- 210000003719 b-lymphocyte Anatomy 0.000 description 2
- 230000001580 bacterial effect Effects 0.000 description 2
- 239000013592 cell lysate Substances 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- 230000003632 chemoprophylactic effect Effects 0.000 description 2
- 238000003776 cleavage reaction Methods 0.000 description 2
- 235000018417 cysteine Nutrition 0.000 description 2
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 description 2
- 238000003745 diagnosis Methods 0.000 description 2
- 230000005284 excitation Effects 0.000 description 2
- 239000012634 fragment Substances 0.000 description 2
- 102000037865 fusion proteins Human genes 0.000 description 2
- 108020001507 fusion proteins Proteins 0.000 description 2
- 230000001900 immune effect Effects 0.000 description 2
- 238000011534 incubation Methods 0.000 description 2
- 239000012678 infectious agent Substances 0.000 description 2
- 230000005764 inhibitory process Effects 0.000 description 2
- 238000003780 insertion Methods 0.000 description 2
- 230000037431 insertion Effects 0.000 description 2
- 230000003071 parasitic effect Effects 0.000 description 2
- 238000010647 peptide synthesis reaction Methods 0.000 description 2
- 239000012071 phase Substances 0.000 description 2
- 238000003752 polymerase chain reaction Methods 0.000 description 2
- 230000007017 scission Effects 0.000 description 2
- 238000012216 screening Methods 0.000 description 2
- 238000001542 size-exclusion chromatography Methods 0.000 description 2
- 239000007787 solid Substances 0.000 description 2
- 239000007790 solid phase Substances 0.000 description 2
- 239000007858 starting material Substances 0.000 description 2
- 108091007196 stromelysin Proteins 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- YBYIRNPNPLQARY-UHFFFAOYSA-N 1H-indene Chemical compound C1=CC=C2CC=CC2=C1 YBYIRNPNPLQARY-UHFFFAOYSA-N 0.000 description 1
- 241000256118 Aedes aegypti Species 0.000 description 1
- 108010088751 Albumins Proteins 0.000 description 1
- 102000009027 Albumins Human genes 0.000 description 1
- APKFDSVGJQXUKY-KKGHZKTASA-N Amphotericin-B Natural products O[C@H]1[C@@H](N)[C@H](O)[C@@H](C)O[C@H]1O[C@H]1C=CC=CC=CC=CC=CC=CC=C[C@H](C)[C@@H](O)[C@@H](C)[C@H](C)OC(=O)C[C@H](O)C[C@H](O)CC[C@@H](O)[C@H](O)C[C@H](O)C[C@](O)(C[C@H](O)[C@H]2C(O)=O)O[C@H]2C1 APKFDSVGJQXUKY-KKGHZKTASA-N 0.000 description 1
- 241001147672 Ancylostoma caninum Species 0.000 description 1
- 241000193830 Bacillus <bacterium> Species 0.000 description 1
- 244000063299 Bacillus subtilis Species 0.000 description 1
- 235000014469 Bacillus subtilis Nutrition 0.000 description 1
- 201000004569 Blindness Diseases 0.000 description 1
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 1
- 241000701822 Bovine papillomavirus Species 0.000 description 1
- 241000244202 Caenorhabditis Species 0.000 description 1
- 241000283707 Capra Species 0.000 description 1
- 108020004705 Codon Proteins 0.000 description 1
- 108020004635 Complementary DNA Proteins 0.000 description 1
- 108091035707 Consensus sequence Proteins 0.000 description 1
- 239000003155 DNA primer Substances 0.000 description 1
- 102000004163 DNA-directed RNA polymerases Human genes 0.000 description 1
- 108090000626 DNA-directed RNA polymerases Proteins 0.000 description 1
- 238000002965 ELISA Methods 0.000 description 1
- 102000016942 Elastin Human genes 0.000 description 1
- 108010014258 Elastin Proteins 0.000 description 1
- 241000283073 Equus caballus Species 0.000 description 1
- 241000701959 Escherichia virus Lambda Species 0.000 description 1
- 102000018389 Exopeptidases Human genes 0.000 description 1
- 108010091443 Exopeptidases Proteins 0.000 description 1
- 241000242711 Fasciola hepatica Species 0.000 description 1
- 201000006353 Filariasis Diseases 0.000 description 1
- 229930182566 Gentamicin Natural products 0.000 description 1
- CEAZRRDELHUEMR-URQXQFDESA-N Gentamicin Chemical compound O1[C@H](C(C)NC)CC[C@@H](N)[C@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](NC)[C@@](C)(O)CO2)O)[C@H](N)C[C@@H]1N CEAZRRDELHUEMR-URQXQFDESA-N 0.000 description 1
- 102000003886 Glycoproteins Human genes 0.000 description 1
- 108090000288 Glycoproteins Proteins 0.000 description 1
- 241000243974 Haemonchus contortus Species 0.000 description 1
- 239000012981 Hank's balanced salt solution Substances 0.000 description 1
- 241000701044 Human gammaherpesvirus 4 Species 0.000 description 1
- XUJNEKJLAYXESH-REOHCLBHSA-N L-Cysteine Chemical compound SC[C@H](N)C(O)=O XUJNEKJLAYXESH-REOHCLBHSA-N 0.000 description 1
- FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 description 1
- 102000002704 Leucyl aminopeptidase Human genes 0.000 description 1
- 108010004098 Leucyl aminopeptidase Proteins 0.000 description 1
- 241000255640 Loa loa Species 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 241000530522 Mansonella ozzardi Species 0.000 description 1
- 241000142895 Mansonella perstans Species 0.000 description 1
- 241000699666 Mus <mouse, genus> Species 0.000 description 1
- 241000639706 Onchocerca cervipedis Species 0.000 description 1
- 241000243985 Onchocerca volvulus Species 0.000 description 1
- 241000283973 Oryctolagus cuniculus Species 0.000 description 1
- 238000012408 PCR amplification Methods 0.000 description 1
- 102000016387 Pancreatic elastase Human genes 0.000 description 1
- 108010067372 Pancreatic elastase Proteins 0.000 description 1
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 1
- 102000004160 Phosphoric Monoester Hydrolases Human genes 0.000 description 1
- 108090000608 Phosphoric Monoester Hydrolases Proteins 0.000 description 1
- ONIBWKKTOPOVIA-UHFFFAOYSA-N Proline Natural products OC(=O)C1CCCN1 ONIBWKKTOPOVIA-UHFFFAOYSA-N 0.000 description 1
- 108020004511 Recombinant DNA Proteins 0.000 description 1
- 241000242680 Schistosoma mansoni Species 0.000 description 1
- 241001520865 Schistosomatium douthitti Species 0.000 description 1
- 238000002105 Southern blotting Methods 0.000 description 1
- 241000187747 Streptomyces Species 0.000 description 1
- 108090001109 Thermolysin Proteins 0.000 description 1
- 241000244030 Toxocara canis Species 0.000 description 1
- 239000007983 Tris buffer Substances 0.000 description 1
- 206010047697 Volvulus Diseases 0.000 description 1
- 241000244002 Wuchereria Species 0.000 description 1
- 241000244005 Wuchereria bancrofti Species 0.000 description 1
- 101000998548 Yersinia ruckeri Alkaline proteinase inhibitor Proteins 0.000 description 1
- DLELKZFCVLJXKZ-GOTSBHOMSA-N Z-Arg-Arg-NHMec Chemical compound N([C@@H](CCCN=C(N)N)C(=O)N[C@@H](CCCN=C(N)N)C(=O)NC1=CC=2OC(=O)C=C(C=2C=C1)C)C(=O)OCC1=CC=CC=C1 DLELKZFCVLJXKZ-GOTSBHOMSA-N 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 235000001014 amino acid Nutrition 0.000 description 1
- APKFDSVGJQXUKY-INPOYWNPSA-N amphotericin B Chemical compound O[C@H]1[C@@H](N)[C@H](O)[C@@H](C)O[C@H]1O[C@H]1/C=C/C=C/C=C/C=C/C=C/C=C/C=C/[C@H](C)[C@@H](O)[C@@H](C)[C@H](C)OC(=O)C[C@H](O)C[C@H](O)CC[C@@H](O)[C@H](O)C[C@H](O)C[C@](O)(C[C@H](O)[C@H]2C(O)=O)O[C@H]2C1 APKFDSVGJQXUKY-INPOYWNPSA-N 0.000 description 1
- 229960003942 amphotericin b Drugs 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 229940088710 antibiotic agent Drugs 0.000 description 1
- 210000000628 antibody-producing cell Anatomy 0.000 description 1
- 229940127090 anticoagulant agent Drugs 0.000 description 1
- 239000003146 anticoagulant agent Substances 0.000 description 1
- 108010058966 bacteriophage T7 induced DNA polymerase Proteins 0.000 description 1
- 239000011324 bead Substances 0.000 description 1
- 125000001584 benzyloxycarbonyl group Chemical group C(=O)(OCC1=CC=CC=C1)* 0.000 description 1
- 108010085937 benzyloxycarbonyl-phenylalanylarginine-4-methylcoumaryl-7-amide Proteins 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 230000010261 cell growth Effects 0.000 description 1
- 230000009134 cell regulation Effects 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 238000012512 characterization method Methods 0.000 description 1
- 239000007795 chemical reaction product Substances 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 239000013599 cloning vector Substances 0.000 description 1
- 230000002860 competitive effect Effects 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 239000000470 constituent Substances 0.000 description 1
- 239000000356 contaminant Substances 0.000 description 1
- 239000000287 crude extract Substances 0.000 description 1
- 230000000593 degrading effect Effects 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 238000000502 dialysis Methods 0.000 description 1
- 229940042399 direct acting antivirals protease inhibitors Drugs 0.000 description 1
- 229940099686 dirofilaria immitis Drugs 0.000 description 1
- 229920002549 elastin Polymers 0.000 description 1
- 208000006036 elephantiasis Diseases 0.000 description 1
- 210000002257 embryonic structure Anatomy 0.000 description 1
- 230000008029 eradication Effects 0.000 description 1
- 230000007717 exclusion Effects 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 238000000855 fermentation Methods 0.000 description 1
- 230000004151 fermentation Effects 0.000 description 1
- 239000012894 fetal calf serum Substances 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 230000004927 fusion Effects 0.000 description 1
- 238000002523 gelfiltration Methods 0.000 description 1
- 229960002518 gentamicin Drugs 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 230000012010 growth Effects 0.000 description 1
- 239000001963 growth medium Substances 0.000 description 1
- ZJYYHGLJYGJLLN-UHFFFAOYSA-N guanidinium thiocyanate Chemical compound SC#N.NC(N)=N ZJYYHGLJYGJLLN-UHFFFAOYSA-N 0.000 description 1
- 244000000013 helminth Species 0.000 description 1
- 238000004128 high performance liquid chromatography Methods 0.000 description 1
- 230000000409 histolytic effect Effects 0.000 description 1
- 230000005847 immunogenicity Effects 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 238000011081 inoculation Methods 0.000 description 1
- 201000007647 intestinal volvulus Diseases 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 238000004255 ion exchange chromatography Methods 0.000 description 1
- 239000004816 latex Substances 0.000 description 1
- 229920000126 latex Polymers 0.000 description 1
- 231100001231 less toxic Toxicity 0.000 description 1
- 239000003446 ligand Substances 0.000 description 1
- 210000004962 mammalian cell Anatomy 0.000 description 1
- 230000001404 mediated effect Effects 0.000 description 1
- 239000003475 metalloproteinase inhibitor Substances 0.000 description 1
- 229930182817 methionine Natural products 0.000 description 1
- 230000011987 methylation Effects 0.000 description 1
- 238000007069 methylation reaction Methods 0.000 description 1
- 235000013336 milk Nutrition 0.000 description 1
- 239000008267 milk Substances 0.000 description 1
- 210000004080 milk Anatomy 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 230000004899 motility Effects 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- 231100000590 oncogenic Toxicity 0.000 description 1
- 230000002246 oncogenic effect Effects 0.000 description 1
- 238000005457 optimization Methods 0.000 description 1
- 230000001590 oxidative effect Effects 0.000 description 1
- 206010033675 panniculitis Diseases 0.000 description 1
- 239000008188 pellet Substances 0.000 description 1
- 239000000137 peptide hydrolase inhibitor Substances 0.000 description 1
- 238000003359 percent control normalization Methods 0.000 description 1
- 239000002504 physiological saline solution Substances 0.000 description 1
- 230000001323 posttranslational effect Effects 0.000 description 1
- 230000003389 potentiating effect Effects 0.000 description 1
- 238000001556 precipitation Methods 0.000 description 1
- 230000037452 priming Effects 0.000 description 1
- 102000004196 processed proteins & peptides Human genes 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 229940024999 proteolytic enzymes for treatment of wounds and ulcers Drugs 0.000 description 1
- 210000001147 pulmonary artery Anatomy 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 229920006395 saturated elastomer Polymers 0.000 description 1
- 230000002000 scavenging effect Effects 0.000 description 1
- 238000012163 sequencing technique Methods 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 238000004513 sizing Methods 0.000 description 1
- 210000003491 skin Anatomy 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 1
- 238000010532 solid phase synthesis reaction Methods 0.000 description 1
- 238000000527 sonication Methods 0.000 description 1
- 210000004304 subcutaneous tissue Anatomy 0.000 description 1
- 229940031626 subunit vaccine Drugs 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 230000001502 supplementing effect Effects 0.000 description 1
- 230000002194 synthesizing effect Effects 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 239000003440 toxic substance Substances 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 238000001890 transfection Methods 0.000 description 1
- 230000009466 transformation Effects 0.000 description 1
- IEDVJHCEMCRBQM-UHFFFAOYSA-N trimethoprim Chemical compound COC1=C(OC)C(OC)=CC(CC=2C(=NC(N)=NC=2)N)=C1 IEDVJHCEMCRBQM-UHFFFAOYSA-N 0.000 description 1
- 229960001082 trimethoprim Drugs 0.000 description 1
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 1
- 238000000108 ultra-filtration Methods 0.000 description 1
- 230000002792 vascular Effects 0.000 description 1
- 210000004509 vascular smooth muscle cell Anatomy 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/14—Hydrolases (3)
- C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
- C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
- C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
- C12N9/6402—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from non-mammals
- C12N9/6405—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from non-mammals not being snakes
- C12N9/641—Cysteine endopeptidases (3.4.22)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
- A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
- A61P33/10—Anthelmintics
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/14—Hydrolases (3)
- C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
- C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
- C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
- C12N9/6402—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from non-mammals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/43504—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from invertebrates
- G01N2333/43526—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from invertebrates from worms
- G01N2333/4353—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from invertebrates from worms from nematodes
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/90—Enzymes; Proenzymes
- G01N2333/914—Hydrolases (3)
- G01N2333/948—Hydrolases (3) acting on peptide bonds (3.4)
- G01N2333/95—Proteinases, i.e. endopeptidases (3.4.21-3.4.99)
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/90—Enzymes; Proenzymes
- G01N2333/914—Hydrolases (3)
- G01N2333/948—Hydrolases (3) acting on peptide bonds (3.4)
- G01N2333/95—Proteinases, i.e. endopeptidases (3.4.21-3.4.99)
- G01N2333/964—Proteinases, i.e. endopeptidases (3.4.21-3.4.99) derived from animal tissue
- G01N2333/96402—Proteinases, i.e. endopeptidases (3.4.21-3.4.99) derived from animal tissue from non-mammals
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Wood Science & Technology (AREA)
- Veterinary Medicine (AREA)
- Zoology (AREA)
- Genetics & Genomics (AREA)
- Medicinal Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- General Health & Medical Sciences (AREA)
- Biotechnology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Animal Behavior & Ethology (AREA)
- Molecular Biology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmacology & Pharmacy (AREA)
- General Chemical & Material Sciences (AREA)
- Microbiology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Public Health (AREA)
- Biochemistry (AREA)
- General Engineering & Computer Science (AREA)
- Enzymes And Modification Thereof (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Description
PROTEASE VACCINE AGAINST HEARTWORM
Technical Field
The invention relates to prevention and treatment of nematode-caused filarial disease in animal hosts, such as heartworm which occurs most commonly in dogs. Heartworm infection is caused by the nematode Dirofilaria immitis. and the treatment and prevention method of the invention can be applied specifically to this disease by employing the characteristic metallo- protease and/or cysteine protease associated with this organism.
Background Art
The heartworm infection caused by D^. immitis is a widely distributed problem in dogs in most regions of the world with the exception of Africa. Current treatment is generally chemoprophylactic with agents designed to directly kill the infecting organisms. While this treatment has gained acceptance, because of the inherent toxicity of such treatment, it would be preferable to immunologically protect the host against infection, or to revise the chemoprophylactic regime to include less toxic agents. The present invention is directed to this goal. Other nematode filarial infections are of even greater significance and involve life cycles of the infectious agent similar to those related to heartworm. For example, of more concern are the other filarids which infect humans, and more than 200 million people worldwide are estimated to have such infections. Filarids which
infect humans include Brugia malayi. Wuchereria bancrof i, and Onchocerca volvulus. These are serious infections which can cause blindness and elephantiasis in humans. At present, there is no effective vaccine available against filarial nematode infection.
As the life cycles of the infectious agents are similar in all of these diseases, heartworm infection can be used as an illustration. This life cycle can be described as follows: Heartworm infection, specifically in dogs, generally occurs through passage of the third-stage larvae (L3) of the nematode D^. immitis into the subcutaneous tissue from a mosquito vector. When these larvae are passed into the animal's tissue, their life cycle is continued by molting into a fourth larval stage ( 4) , which then migrates toward the heart and pulmonary arteries where the subsequent stage matures into an adult. The L3 remain at the site of inoculation by the mosquito until molting occurs. L4 emigrate through cutaneous tissue and muscle and do not molt to fifth stage for 50-70 days after infection (Grieve, R. , et al., Epidem Rev (1983) £:220-246) . Adult D_-_ immitis. which are on the order of 12-20 cm (males) and 25-31 cm (females) in length, produce, in this location, motile vermiform embryos called microfilariae, which are only 0.3 mm long and which traverse capillary beds and circulate in the vascular system. The microfilariae are ingested by mosquitoes and continue their life cycle through L3 in the mosquito vector. The transition from L3 to 4 is thus the initial step in the infection cycle in the animal .host. This transition involves a molting process, which has been studied by Abraham, D., et al., Experimental Parasitol (1990) 7_:314-322, incorporated herein by reference*. In this study, the morphology of the larvae
during the molt was monitored, and the roles of temperature and of albumin, which appeared to be essential for this process, were evaluated. The 3 stage contains a cuticle and epicuticle which are abandoned, and the body wall of the larva is encased in the L4 stage cuticle and epicuticle. During this molting process, an excretory-secretory (E-S) product which, among other components, contains enzymes presumably employed in the molting process is formed. The excretory-secretory products of various tissue invasive helminths have been studied. Proteases have been found in a number of them. Both Schistosoma mansoni and Schistosomatium douthitti produce elastases capable of degrading skin (McKerrow, J.H., et al., Experimental Parasitol (1982) 5 :2 9; McKerrow, J.H., et al., J Biol Chem (1985) 231:47: Amiri, P., et al., Mol Biochem Parasitol (1988) 28..H3) . Fasciola hepatica also releases a number of proteolytic enzymes (Dalton, J.P., et al., Mol Biochem Parasitol (1989) 15:161) . The adult hookworm Ancylostoma caninum releases a histolytic protease and a protease that acts as an anticlotting agent (Hotez, P.J., et al., J Biol Chem (1985) 2 0:7343) . Toxocara canis larvae secrete proteases which degrade components of extracellular matrix (Robertson, B.D., et al., Experimental Parasitol (1989) 69:30) .
A number of filarial nematodes also have been shown to produce proteases that act on extracellular matrix components, including Onchocerca cervipedis. 0. cervicalis. and Bru ia malayi (Lackey, A., et al., Experimental Parasitol (1989) £8.176; Petralanda, I., et al., Mol Biochem Parasitol (1986) 19.:51) . The protease activity includes collagenase in the case of Brugia malayi. 0. cervicalis and Cx. cervipedis. A collagenase and a leucine aminopeptidase have been found in the molting process of Haemonchus contortus by Rogers, W.P.,
J Parasitol (1982) 12:495, and Gamble, H.R. , et al., Mol Biochem Parasitol (1989) 11:49.
With respect to EL, immitis. protease activity has been detected in soluble extracts of D. -jrc itis adults by Maki, J., et al., J Helminthol (1986) ££:3l-37, and in extracts of microfilariae by Tomashiro, W.K., et al., J Parasitol (1987) 71:149-154. However, the soluble extracts of ~H_, immitis L3 and L4 and the excretory- secretory (E-S) products of these larval stages have not previously been studied.
It is also known that collagens form the major structural components of nematode cuticle by virtue of studies conducted on Caenorhabditis eleσans. B. malayi, and | _ pahancri.
Disclosure of the Invention
The invention is directed to prevention -and treatment of filarial nematode infection in animal hosts and to purified and isolated forms of the proteases associated with the L3 and L4 larval stages of the parasites that cause these infections. One of these nematodes is Dirofilaria immitis. which causes heartworm in dogs. Other diseases of importance are caused by nematodes such as those listed above. The invention provides an approach to the eradication of conditions caused in animals by filarial nematodes, and provides materials useful in these and in in vitro contexts.
Accordingly, in one aspect, the invention is directed to a method to protect animal subjects, including humans, against filarial nematode infection, which method comprises administering to the subject an effective amount of a metalloprotease and/or cysteine protease characteristic of transition from the I-3-L4 stage of the relevant filarial nematode effective to i πtunologically protect the subject against infection.
225 - 5 -
The characteristic metalloprotease(s) may be found in the L3 or L4 excretory-secretory material or in L3 or L4 lysates. The cysteine protease is found in L3 and L4 lysates. In another aspect, the invention is directed to the treatment of nematode filarial infection in animal subjects, including humans, which method comprises administering to that subject an effective amount of a metalloprotease inhibitor and/or cysteine protease inhibitor.
In other aspects, the invention is directed to antibodies immunospecific for filarial L3 or L4 excretory-secretory products or L3 or L4 lysate metalloprotease(s) or to L3 or L4 lysate cysteine protease(s) and to pharmaceutical compositions and vaccines containing them.
In still another aspect, the invention is directed to the L3/L4-associated metalloproteases and cysteine proteases of filarial parasites in isolated and purified form. These purified proteases are additionally useful to assay for the presence or absence of antibodies in the diagnosis of affected individuals and to regulate the growth of cell cultures in vitro, as well as in other therapeutic applications.
Brief Description of the Drawings
Figure 1 shows the elution pattern of protease activity from L3/L4 E-S.
Figure 2 shows the elution pattern of protease activity from L4 lysate.
Modes of Carrying Out the Invention
As used herein, "metalloprotease" of L3 and L4 excretory-secretory preparation (L3 and L4 E-S) or of L3 or L4 lysates refers to metalloprotease enzymes characteristic of the excretory-secretory products obtained during the molting of the L3 larval stage into L4 for filarial infective nematodes; or of whole worm lysates of the L3 or L4 larval stage. At least one "cysteine protease" is also found in L3 and L4 lysates. While the E-S and lysate preparations from _____ immitis are exemplified below, similar E-S or lysate preparations can be obtained from various other filarial parasites such as those set forth in the Background section above, and including, specifically, for example, &_,__ malayi. H__ bancrofti, Q,. volvulus. Dipetalonema perstans. ______ streptocerca. Mansonella ozzardi, and Loa loa.
Preparation of Larval Cultures
The parasites can be cultured in vitro under suitable conditions to provide a source for the E-S preparation or for the L3 or L4 lysates. For example, D. immitis can be cultured as described by Abraham, D., et al., J Parasitol (1987) 71:377-383. Briefly, the mosquito Aedes aegypti Liverpool (black-eyed strain) are infected with 2^ immitis by feeding on microfilaremic blood obtained from a single experimentally infected dog. Fifteen days after feeding, the mosquitos are anesthetized, surface sterilized and placed on screens in funnels filled with a 1:1 mixture of NCTC-135 and Iscove's modified Dulbecco medium (Sigma) containing
2.5 μg/ml amphotericin-B; 100 μg/ml gentamicin; 50 μg/ml sulfadiazone? and 10 μg/ml trimethoprim. The larvae are collected from funnels 90 minutes postincubation.
The cultures are maintained at a concentration of ten L3 organisms per ml of medium in 5% C02 and
saturated humidity. The larvae (L3) are cultured at 37° in the foregoing medium, supplemented with 20% fetal calf serum for 1-8 days.
Alternatively, and preferably, 10 days after feeding, the mosquitos are anesthetized and the worms are recovered by dissecting the heads and allowing the worms to emerge into medium with 20% Seru-max (Sigma) to induce molting. After 48 hr, the worms are recovered, washed 5 times in medium which does not contain Seru-max, and recultured therein.
Preparation of L3 and L4 E-S
L3 ES is collected between 48 and 96 hours of culture on Seru-max free medium. L4 ES is collected between 96 and 144 hours in inden ical culture conditions. Medium containing ES is collected and filtered through a 0.45 μm filter. The ES is concentrated and the buffer is exchanged into pH 7.2 PBS using ultrafiltration and 10 kd exclusion limit to obtain the fraction of >10 kd M .
Preparation of L3 and L4 Lysates
Larval soluble extracts are prepared from L3 collected on day 2, just after the wash but prior to the molt, and L4 are collected on day 6 in serum-free culture. Pellets of 10,000 worms in PBS are disrupted by ten 10-sec high frequency pulses using a tissue sonicator. Sonicated worms are centrifuged for 5 min at 12,000 x g, and the supernatant collected.
Determination of E-S and Lysate Components
Protein concentration for both E-S and whole worm soluble extracts may be estimated using a Micro BCA kit (Pierce Chemical Co., Rockford, IL) . All samples are maintained at -20° C prior to further analysis.
By "metalloprotease" of the L3 and L4 E-S preparation or of L3 or L4 lysates is meant a protease enzyme which is found in the excretory-secretory product of third or fourth stage larvae or in L3 or L4 lysates of a filarial nematode parasite as ascertained by activity against the synthetic substrate h-phenylalanine-AMC (h-F- AMC, defined below) and which is inhibited by metallo¬ protease inhibitors such as 1,10-phenanthroline and EDTA. Metalloprotease activity has been reported in E-S products of third stage larvae of certain species, including B^. malayi, 0. cervicalis. and Q. cervipedis as set forth above. The activity is also present in L3 and L4 lysates.
The invention also relates to "cysteine protease(s) " from L3 or L4 lysates, which lysates may be prepared as described above. The cysteine proteases of the invention are characterized by ability to hydrolyze Z-valine-leucine-arginine-AMC (Z-VLR-AMC, defined below) and this activity is inhibited by E64. Again, . immitis is used for illustration below, but other filarial nematodes may be used.
Both of these enzymes may be obtained in purified and isolated form using chromatographic methods with use of the appropriate substrate assay to monitor elution fractions as further described below.
Because of the practical difficulties in obtaining sufficient quantities of the metalloprotease of L3 and L4 E-S preparations or the metalloprotease' or cysteine protease from L3 or L4 lysates to provide material for vaccines, alternative methods of production are preferred when large quantities are desired. Specifically, for the full-length metalloprotease or cysteine protease, recombinant production is the most practical approach; for immunogenic subunits which are capable of eliciting antibodies that neutralize the
metalloprotease or cysteine protease activity, ordinary solid phase peptide synthesis may be preferred. However, even in this instance, it may be desirable to utilize recombinant production to obtain tandem repeats of the immunogenic subunit. Production of tandem repeats may enhance the immunogenicity of the material. In addition, the subunit vaccines may be recombinantly produced as fusion proteins to an immunogenicity-conferring sequence.
Recombinant Production
The recombinant sequences necessary for production of the relevant metalloprotease or cysteine protease are obtained in a process analogous to that described by Sakanari, J.A. , et al., Proc Natl Acad Sci (1989) 8j6:4863. in this process, the gene encoding the metalloprotease or cysteine protease is isolated from cDNA prepared from total mRNA of the L3 or L4 stage of the parasite using oligonucleotide primers and the polymerase chain reaction (PCR) and suitable probes. Dj_ immitis genomic or cDNA is used as a source for protease-encoding genes. For isolation of the metalloprotease gene, primers are designed based on consensus sequences in the bacterial metalloprotease thermolysin, and members of the human metalloprotease family which include stromelysin, stromelysin II, and Pump-I. These highly homologous genes are all metalloproteases, and the cDNAs containing these sequences have been disclosed (Muller, D., et al., Biochem J (1988) 2^1:187-192 and Quantin, B., et al., Biochemistry (1989) 28.:5327-5334) . Primers can be designed based on the conserved regions, including, the active site. PCR amplification is conducted as described by Sakanari et al. (supra) , and reaction products are loaded on agarose/NuSieve (FMC) . An additional probe designed based on the above-mentioned published sequences
is used to identify the relevant amplified gene products on Southern blots. The fragments are cut out of the gel, extracted with "glass milk" (Geneclean) and ligated into Bluescript (Stratagene) to obtain sequences of both coding and anticoding strands, using the dideoxy method of Sanger with Sequenase (USB) and the SK and KS primers for sequencing in both directions. The gene fragments obtained are then used as probes to screen a cDNA library. They are labeled with 32P using standard random priming methods.
For preparation of analogous probes for the cysteine protease genes, primers are designed based on the sequences disclosed in Eakin, A.E. et al., Mol Biochem Parasitol (1990) l :l-8. Otherwise, the retrieval of probes from genomic DNA can be conducted as above.
The cDNA library is constructed from messenger RNA isolated from third stage larvae which have been in culture for 48-72 hours. The mRNA is isolated by the single step acid guanidinium thiocyanate/phenol/ chloroform extraction method of Chomczynski, P. and Sacchi, N., Anal Biochem (1987) 1£2:156-159. The RNA is passed over an oligo-dT cellulose column and the poly-A RNA is eluted using standard procedures. cDNA is prepared from the mRNA using standard procedures such as those of Gubler, U. and Hoffman, B.J., Gene (1983) 2J 263. The cDNA is treated by methylation of internal EcoRI sites, and phosphorylated EcoRI linkers are added to the ends of the cDNA and treated again with phosphatase. The treated cDNA contain linkers digested with EcoRI to generate cohesive cloning ends for insertion into λ-gtll arms (Stratagene, San Diego, CA) and packaged using Gigapack (Stratagene) . Standard methods are used to titer and plate the library for screening.
The library can be screened either using the probes obtained as described above, heterologous probes, or the expression products can be screened using antibodies prepared against the proteases obtained from the E-S product or lysates. Selected clones are plaque purified, and the isolated coding sequences are used to produce the recombinant protease.
The cloned DNA can be used directly in expression vectors, or DNA can be synthesized using standard solid phase techniques to obtain any embodiment of the coding sequence to supply all or a portion of the gene.
For example, a DNA coding sequence for the protease can be prepared synthetically from overlapping oligonucleotides whose sequence contains codons for the amino acid sequence encoded in the native gene. Such oligonucleotides are prepared by standard methods and assembled into a complete or partial coding sequence. See, e.g., Edge, Nature (1981) 292:756; Nambair et al., Science (1984) 223:1299; Jay et al. , J Biol Chem (1984) 2≤9:6311.
Thus, a DNA molecule containing the coding sequence for the filarial nematode metalloprotease or cysteine protease can be cloned in any suitable vector and thereby maintained in a composition substantially free of vectors that do not contain the coding sequence for the protease (e.g., other library clones). Numerous cloning vectors are known to those of skill in the art, and the selection of an appropriate cloning vector is a matter of choice. Examples of recombinant DNA vectors for cloning and the host cells which they transform include bacteriophage λ (EL. coli) , pBR322 (EL. coli) , pACYC177 (EL. coli) , pKT230 (gram-negative bacteria) , pBG1106 (gram-negative bacteria) , pLAFRl (gram-negative bacteria) , pME290 (non-J _ coli gram-negative bacteria) ,
pHV14 (IL. coli and Bacillus subtilis) , pBD9 (Bacillus) , pIJ61 (Streptomvces) , pUC6 (Streptomyces) , actinophage C31 (Streptomvces) , YIp5 (yeast) , YCpl9 (yeast) , and bovine papilloma virus (mammalian cells) . For expression, the coding sequence of the protease gene is placed under the control of a promoter, ribosome binding site (for bacterial expression) and, optionally, an operator (collectively referred to herein as "control" sequences) so that the protease-encoding sequence is transcribed into RNA in the host cell transformed by the vector. The coding sequence may or may not contain a signal peptide or leader sequence. In bacteria, the protease is preferably produced by the expression of a coding sequence which does not contain any native signal peptide, or by expression of a coding sequence containing the leader sequence in a eucaryotic system when post-translational processing removes the leader sequence. The protease can also be expressed in the form of a fusion protein, wherein a heterologous amino acid sequence is expressed at the N- or C-terminus. See, e.g., U.S. Patent Nos. 4,431,739; 4,425,437.
The recombinant vector is constructed so that the protease-encoding sequence is located in the vector with the appropriate control sequences, the positioning and orientation of the coding sequence with respect to the control sequences being such that the coding sequence is transcribed under the control of the control sequences (i.e., by RNA polymerase which attaches to the DNA molecule at the control sequences) . The control sequences may be ligated to the coding sequence prior to insertion into a vector, such as the cloning vectors described above. Alternatively, the coding sequence can be cloned directly into an expression vector which already contains the control sequence and an appropriate restriction site downstream from control sequences. For
expression of the protease-encoding sequence in other than nematodes, the control sequences will be heterologous to the coding sequence. If the host cell is a procaryote, it is also necessary that the coding sequence be free of introns; e.g., cDNA. If the selected host cell is a nematode cell, the control sequences can be heterologous or homologous to the protease-encoding sequence, and the coding sequence can be genomic DNA containing introns or cDNA. Either genomic or cDNA coding sequences may be also expressed in yeast.
A number of procaryotic expression vectors are known in the art. See, e.g., U.S. Patent Nos. 4,440,859; 4,436,815; 4,431,740; 4,431,739; 4,428,941; 4,425,437; 4,418,149; 4,411,994; 4,366,246; 4,342,832. Preferred expression vectors, however, are those for use in eucaryotic systems. Yeast expression vectors are known in the art. See, e.g., U.S. Patent Nos. 4,446,235; 4,443,539; 4,430,428. See also European Patent Specifications 103,409; 100,561; 96,491. The recombinant protease can be produced by growing host cells transformed by the expression vector described above under conditions whereby the protease is produced. Human collagenase cDNA has been cloned and expressed in active form in eucaryotic cells (Muller, D., et al., Biochem J (1988) 253:187-192) . The protease is then isolated from the host cells and purified. If the expression system secretes the protease into growth media, the desired protein can be purified directly from cell-free media. If the protease is not secreted, it is isolated from cell lysates. The selection of the appropriate growth conditions and recovery methods •are within the skill of the art; purifications similar to those exemplified below can be used.
Antibodv Production
Either native or recombinant proteases of the invention can be used to produce antibodies, both polyclonal and monoclonal. If polyclonal antibodies are desired, the purified protease is used to immunize a selected mammal (e.g., mouse, rabbit, goat, horse, etc.) and serum from the immunized animal later collected and treated according to known procedures. Compositions containing polyclonal antibodies to a variety of antigens in addition to the relevant protease can be made substantially free of antibodies which are not protease antibodies by passing the composition through a column to which the desired protease has been bound. After washing, polyclonal antibodies are eluted from the column. Monoclonal antibodies can also be readily produced by one skilled in the art. The general methodology for making monoclonal antibodies by hybridomas is well known. Immortal, antibody-producing cell lines can also be created by techniques other than fusion, such as direct transformation of B lymphocytes with oncogenic DNA, or transfection with Epstein-Barr virus. See, e.g., Schreier, M., et al., HYBRIDOMA TECHNIQUES (1980); Hammerling et al., MONOCLONAL ANTIBODIES AND T-CELL HYBRIDOMAS (1981); Kennett et al., MONOCLONAL ANTIBODIES (1980) .
By employing the metalloprotease or cysteine protease (native or synthetic) as an antigen in the immunization of the source of the B-cells immortalized for the production of monoclonal antibodies, a panel of monoclonal antibodies recognizing epitopes at different sites on the protease can be obtained. Antibodies which recognize an epitope in the active site binding region of the protease can be readily identified in competition assays between antibodies and enzyme substrate. Artificial substrates such as Z-VLR-AMC (cysteine
protease) or h-F-AMC (metalloprotease) can also be used. Such antibodies have therapeutic potential if they are able to block the binding of protease to its substrate in vivo. Antibodies which recognize a site on the protease are also useful, for example, in the purification of the desired protease protein from cell lysates or fermentation media, and in its characterization. In general, as is known in the art, the protease antibody is fixed (immobilized) to a solid support, such as a column or latex beads, contacted with a solution containing the protease, and separated from the solution. The protease, bound to the immobilized antibodies, is then eluted.
Isolation and Purification of the L3 and L4 Proteases As stated above, the cysteine protease characteristic of the L3 and L4 lysates and the metalloprotease characteristic of these lysates, as well as the L3/L4 E-S, can be obtained in isolated and purified form either using the appropriate larval stage of the desired parasitic nematode as starting material, using recombinant production in cell culture and isolating the protease resulting from the cysteine protease or metalloprotease gene expression, or by synthesizing subunits of these proteins using standard peptide synthesis techniques. The nature of the purification method will depend on the origin of the protease or peptide.
When isolated from native sources, the lysate or E-S material is subjected to chromatographic techniques, typically chromatography using affinity chromatography (e.g., affinity chromatography using antibodies prepared with respect to the protease as affinity ligands) , ion-exchange chromatography, sizing columns, reverse-phase columns, and the like. Optimization of the purification procedure is within the
skill of the art, as the fractions eluted from the- columns can be assayed using activity determination with a fluorometric substrate characteristic of the metalloprotease or cysteine protease. For the metalloprotease of D^. immitis. h-F-AMC is a convenient substrate; for the cysteine protease of this worm, Z-VLR-AMC is appropriately used. The specificity and nature of the protease can be verified by supplementing the assay with various inhibitors known to characterize metalloproteases or cysteine proteases. Modified forms of these substrates may be appropriate for the metalloproteases or cysteine proteases of other species of filarial nematodes; the appropriate substrate can be ascertained by the conduct of preliminary assays on the crude extracts, as exemplified herein for the E^. immitis species.
If the protease is produced recombinantly, similar techniques can be used, although the starting material generally contains the protease in a more highly concentrated form. Further modification of the purification procedure is appropriate for isolation of the peptides prepared by solid-phase synthesis, since the nature of the contaminants is different. Generally, dialysis or other size-separation methods are appropriate.
The purified and isolated forms of the cysteine and metalloproteases of the various filarial nematode species can be used in the production of antibodies (which antibodies, in turn, are useful in immunoassays and separation techniques) , as reagents in immunoassay procedures for the presence or absence of antibodies, and in the regulation of cell culture in vitro by controlling extracellular matrix formation or status.
Use of Purified and Isolated Proteases in Diagnosis
The purified and isolated proteases are useful in diagnostic immunoassays for the presence or absence of antibodies with respect to filarial nematode species. These assays can be used to assess the disease state of a host organism or to assay titers in immunization protocols. The assays are conducted in standard immunological format, including RIA, ELISA, and fluorescence-labeled assays. The assays can be conducted in either a direct or a competitive format and rely on separations by virtue of binding to solid support or by virtue of precipitation of immunological complexes. A large number of protocols suitable for the conduct of immunoassays is well known in the art.
Use of Purified and Isolated Proteases in Vaccines
The proteases of the invention are useful as vaccines in immunizing host organisms to protect them against infection by the corresponding filarial nematode. The proteases are administered in standard pharmaceutical formulations systemically, and typically by injection. Injection may be intravenous, intramuscular, peritoneal, or other parenteral. Suitable vehicles for injection include physiological saline, Hank's solution, Ringer's solution and the like, with or without the presence of adjuvants, according to the immunization protocol. Generally, the vaccine is administered at a dosage level sufficient to raise antibody titers to provide effective scavenging of the proteases required for molting from the L3 to the L4 stage in the filarial infective agent.
Treatment of Infection with Inhibitors
As the proteases of the invention are needed for the progression of the parasitic nematode life cycle, administration of inhibitors of these enzymes to infected hosts in suitable dosages inhibits or arrests the course of the infection. The inhibitors are formulated in suitable pharmaceutical compositions such as those described in Remington's Pharmaceutical Sciences, latest edition, Mack Publishing Co., Easton, PA. Administration is preferably by oral formulation, although injection or transdermal or transmucosal routes can also be used.
The following examples are intended to illustrate, but not to limit the invention.
Example 1
Demonstration of Protease Activity in D. Immitis
D. immitis were cultured at a concentration of 100 larvae per ml in a 1:1 mixture of NCTC-135 and Iscove's modified Dulbecco medium (Sigma) containing antibiotics (NI) on a model of extracellular matrix (ECM) secreted by rat vascular smooth muscle cells and labelled with tritiated proline. Every 8 hrs a 50 μl sample was collected and the amount of tritium released from the matrix was counted on a scintillation counter. The counts per minute of tritium released from the ECM for the L3 stage increased slowly from 1 x 104 cpm after 8 hours to about 2 x 104 cpm after 56 hours, when L3 molting occurs. A large incremental release of tritium (indicating degradation of the matrix) occurs at the time of L3 molting; cpm increase to about 6 x 104 cpm after 64 hrs and to over 8 x 104 cpm after 72 hrs. The breakdown of matrix mediated by L4 tracked that by L3 until the 56 hour L3 molt event; cpm for L4 continued to increase only slowly after this (to <4 x 104 cpm after 72 hrs) . In
total, after 72 hours the L3 culture degraded 20% of the total ECM, and the L4 culture degraded 13%.
The components of the ECM which were degraded were evaluated by sequential enzyme digests of the remaining ECM as described previously (McKerrow, J.H., et al., Lab Invest (1983) 49.:195-200.
The results are shown in Table 1. Collagen is shown to be the major component of the ECM degraded by both L3 and L4 lysates. However, L3 lysates degrade nearly twice as much collagen as lysate from L4.
Table 1 Percent Degradation of ECM Constituent Proteins (100 larvae lysate/ml)
Glycoproteins
Elastin
Collagen
In these experiments, controls for nonparasite- derived degradation of ECM constituted either NI alone, mosquito media, or CL_ elegans. Mosquito media were prepared from noninfected mosquito heads processed as if they contained worms. CL. elegans adults and larvae were recovered from NGM agarose plates seeded with EL. coli strain OP50, placed in M9 media at the same concentration as the ____. immitis larvae and incubated at 26°C. Mosquito media were used as a control to assure that mosquito- derived proteases were not responsible for any of the degradation observed. CL_ elegans. a free-living nematode, was used as a comparison to tissue-invasive nematodes and as a control to insure motility alone did not cause release of label.
Lysates from L3 and L4 were prepared by sonication of the larvae in PBS on ice using 10 x 10 sec high frequency pulses. Lysates containing 10 μg protein per reaction were tested against artificial substrates consisting of amino acids linked to a fluorogenic compound, 7-amido-4-methylcoumarin (AMC) (Bache ) . Some substrates were protected against exopeptidase activity by a benzyloxycarbonyl group, abbreviated Z; the substrates that are not protected are indicated by a preceding "h". These substrates are Z-Val-Leu-Arg-AMC, h-Phe-AMC, Z-Phe-Arg-AMC, and Z-Arg-Arg-AMC (abbreviated Z-VLR-AMC, h-F-AMC, Z-FR-AMC, and Z-RR-AMC respectively) . The lysate was incubated with each substrate for 3 hrs, and the amount of AMC hydrolyzed was measured fluorimetrically. Cleavage of AMC was measured using an LS-2 spectrofluorometer (Perkin Elmer) with 380 nm excitation wavelength and emission detection at 460 nm. Initial substrate screening reactions consisted of 10 μl substrate (at 5 mM in DMSO) , 980 μl PBS, pH 7.2, and 10 μl combined L3 and L4 soluble extracts. A number of additional substrates, found to be uncleaved, were also tested: Z-GPLGP-AMC, Z-GPR-AMC, Z-ARR-AMC, Z-AR-AMC, Z- R-AMC and h-L-AMC. However, further work was conducted with the four substrates listed above. Two mM dithio- threitol (DTT) was found to enhance cleavage of Z-VLR-AMC twofold, but to inhibit h-F-AMC hydrolysis as shown in Table 2. Thus, Z-VLR AMC is shown to be a substrate for this cysteine protease, h-F-AMC is a substrate for the metalloprotease.
Table 2
Effect of 2 mM DTT on Hydrolysis of z-VLR-AMC and h-F-AMC by L3 Soluble Extract
Substrate nMoles AMC released/hr
+DTT -DTT
h-Phe-AMC 99.0 (16.7) 326.4 (25.0) z-Val-Leu-Arg-AMC 54.6 (1.7) 32.6 (2.6)
Data represent the means of duplicate samples with ranges indicated in parentheses.
Thereafter, in the determinations, the PBS contained 2 mM DTT except when h-F-AMC was used.
Further, reaction mixtures consisted of 10 μl 5 mM substrate, 10 μl larval soluble extract or E-S at protein concentration of 1 μg/ml and 980 μl of PBS, pH 7.2. After incubation of the lysate or E-S with substrate at 37°C for a specified length of time, the hydrolyzed AMC was measured on a Perkin Elmer LS-2 filter fluorometer with excitation and emission wavelengths as set forth above. For h-F-AMC, the L3 lysate releases about 20 μmol of AMC after the 3 hr incubation while the L4 lysate releases slightly less than 10 μmol. Z-FR-AMC and Z-RR-AMC are not effective substrates for either lysate; approximately 5 μmol of AMC are released from Z- VLR-AMC by either extract.
The excretory-secretory materials were also tested for activity on these substrates. Using 2 μg of protein per reaction, the L3 E-S composition released about 9 μmol AMC from h-F-AMC per reaction mixture after 3 hr whereas the L4 E-S composition released only about 2
μmol. No AMC was released from the Z-VLR-AMC, Z-FR-AMC or Z-RR-AMC substrates.
The effect of inhibitors was also tested with respect to the synthetic substrates Z-VLR-AMC and h-F-AMC using the lysates of L3 and L4 prepared as above. h-F-AMC was shown to be a substrate for this metalloprotease; Z-VLR-AMC was shown to be a substrate for this cysteine protease (DTT enhances cysteine protease activity; oxidizing conditions inhibit it) (see Table 2) . Ten μl (10 μg total protein) of L3 or L4 lysate was mixed with 10 μl 50 μM synthetic peptide substrate, 960 μl PBS buffer, pH 7.2 containing 2 M DTT when Z-VLR-AMC was used and without DTT when h-F-AMC was used. Twenty μl of the test inhibitors were added to the reaction mixtures, the final concentrations of the inhibitors were as follows: PMSF, 2 n-M; 1,10-phenanthro- line, 10 mM; NEM, 2 mM; E-64, 10 mM; Bestatin, 1 mM; Cystatin, 4 μM; and EDTA, 2 mM. Inhibition was calculated as the percent activity remaining as compared to control in absence of the inhibitor. The results are shown in Table 3 (L3) and Table 4 (L4) .
Table 3 L3 Lysate % Control Activity Remaining Substrate
Z-VLR-AMC h-F-AMC
PMSF NEM E64 1,10-Phe
Bestatin Cystatin EDTA
Tab e 4
PMSF
NEM E64
1,10-Phe Bestatin Cystatin
EDTA
E64, a potent cysteine protease inhibitor, had essentially no effect on the metalloprotease substrate h-F-AMC; however, E64 was the most effective inhibitor for the cysteine protease substrate, Z-VLR-AMC.
The activity of L4 lysates with respect to the various fluorogenic synthetic substrates was also tested in the presence and absence of DTT. DTT seemed to enhance the activity with respect to Z-VLR-AMC, Z-FR-AMC and Z-RR-AMC. DTT is known to enhance the activity of cysteine proteases and to inhibit metalloproteases.
The effect of the same inhibitors was tested essentially as described above with respect to the hydrolysis of h-F-AMC by L3 E-S. The reactions contain 10 μl L3 E-S, i.e., 10 μg total protein, 10 μl of the h-F-AMC to give 50 μM final concentration, 960 μl PBS pH 7.2 and 20 μl inhibitor to give final concentrations as for the lysates above. The inhibition pattern, as shown in Table 5, is similar to that shown by the lysates.
Table 5 E-S from L3r % of Control Activity Remaining
Substrate h-F-AMC PMSF 22
NEM 26
E64 79
1,10-Phe 5
Bestatin 80 Cystatin 98
EDTA 5
Taken together, these data show that the lysates and E-S preparations contain metalloprotease, but only the lysates contain significant amounts of cysteine protease activity.
gatarople 2 Preparation of Proteases from D. Immitis The L3 or L4 lysates or the L3/L4 E-S prepared as described above were subjected to size exclusion chromatography.
The L3/L4 E-S of 8,000 larvae, collected from 48 to 144 hours, was concentrated to 75 μl in 0.05 M Tris/HCl, pH 6.8, 0.15 M NaCl, and injected for size exclusion chromatography into a TSK 3,000 SW 7.5 x 300 mm column with a 7.5 x 75 mm guard column (Beckman, Fullerton, CA) attached to Beckman Model 338 HPLC. The mobile phase used the same buffer, the flow rate was 0.5 ml/min and the detector was set at 220 nm. One minute fractions were collected starting at 12 minutes. The column was calibrated using gel filtration molecular weight markers (NW-GF-200) (Sigma) .
The L3/L4 E-S which had been metabolically labeled with S35 methionine and cysteine was collected
and chromatographed under the conditions described above and the fractions were subjected to reducing SDS-]?AGE using standard techniques. Figure 1 shows the chromatogram obtained when h-F-AMC was used as a substrate to assay activity of the fractions--20 μl of each fraction was incubated with 5 mM h-F-AMC in 970 ml PBS, pH 7.2, for 1 hour. Peak enzyme activity was in fraction 10 which corresponded to a molecular weight of approximately 49-58 kd. SDS-PAGE analysis of fraction 10 gave three prominent bands at 58, 30 and 22 kd and three minor bands at 28, 26 and 19 kd under denaturing and reducing conditions.
Similar separations were run using lysates prepared from 6,000 L4 worms collected after 144 hours. The fractions were assayed using both Z-VLR-AMC and h-F-AMC as substrates. The results are shown in Figure 2. The h-F-AMC activity (metalloprotease) eluted at a position corresponding to 49-54 kd; the Z-VLR-AMC activity eluted at a position corresponding to 31-34 kd.
Claims (17)
1. A veterinary or pharmaceutical composition for immunization of an animal host against filarial nematode infection, which composition comprises an amount of at least one protease in purified and isolated form effective to immunize said animal host and which protease is obtainable by isolation from L3 or L4 lysate or from L3/L4 excretory-secretory material of said filarial nematode, or an immunogenic subunit thereof.
2. A veterinary or pharmaceutical composition useful in treating or ameliorating the symptoms of filarial nematode infection in an animal host, which composition comprises an effective amount of an inhibitor of at least one protease which protease is obtainable by isolation from L3 or L4 lysate or from L3/L4 excretory- secretory material of said filarial nematode.
3. The composition of claim 1 or 2 wherein said protease is a metalloprotease or a cysteine protease.
4. The composition of claim 1 or 2 wherein the nematode is O_^ immitis filarial nematode.
5. A method to immunize an animal host, susceptible to infection by a filarial nematode, against said infection, which method comprises: administering to a host in need of such immunization an amount effective to immunize said host of at least one protease in isolated and purified form, which protease is obtainable by isolation from L3 or L4 lysate or from L3/L4 excretory-secretory material of said filarial nematode, or an immunogenic subunit thereof.
6. A method to treat or ameliorate filarial nematode infection in an animal host, which method comprises administering to said host an effective amount of an inhibitor of at least one protease which protease is obtainable by isolation from L3 or L4 lysate or from L3/L4 excretory-secretory material of said filarial nematode.
7. The method of claim 5 or 6 wherein said protease is a metalloprotease or a cysteine protease.
8. The method of claim 5 or 6 wherein the nematode is D^. immitis filarial nematode.
9. Antibodies specifically immunoreactive with at least one protease which is obtainable by isolation from L3 or L4 lysate or from L3/L4 excretory-secretory material of a Dj. immitis filarial nematode, wherein said protease is a cysteine protease or a metalloprotease.
10. A protease obtainable by isolation from the L3 or L4 lysate or from L3/L4 excretory-secretory material of a fij. immitis infective filarial nematode in purified and isolated form, wherein said protease is a metalloprotease or a cysteine protease.
11. A method to purify a protease from an L3 or L4 lysate or from L3/L4 excretory-secretory material of a filarial nematode, which method comprises subjecting said lysate or excretory-secretory material to a column chromatographic procedure and assaying fractions eluted from said column for proteolytic activity on a synthetic substrate characteristic of said protease.
12. The method of claim 11 wherein said protease is a cysteine protease and the substrate is Z-VLR-AMC, or wherein said protease is a metalloprotease and the substrate is h-F-AMC.
13. A peptide which consists essentially of an immunogenic subunit of the purified protease of claim 10.
14. A DNA in purified and isolated form that encodes the protease of claim 10, or the complement thereof.
15. An expression system capable, when transformed into a recombinant host cell, of expressing a DNA encoding the protease of claim 10.
16. Recombinant host cells transformed with the expression system of claim 15.
17. A method to prepare a protease enzyme which method comprises culturing the cells of claim 15 under conditions that effect the expression of said coding sequence and recovering the protease from the cell culture.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US79220991A | 1991-11-12 | 1991-11-12 | |
US792209 | 1991-11-12 | ||
PCT/US1992/009702 WO1993010225A1 (en) | 1991-11-12 | 1992-11-12 | Protease vaccine against heartworm |
Publications (2)
Publication Number | Publication Date |
---|---|
AU3072392A true AU3072392A (en) | 1993-06-15 |
AU675214B2 AU675214B2 (en) | 1997-01-30 |
Family
ID=25156129
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
AU30723/92A Expired AU675214B2 (en) | 1991-11-12 | 1992-11-12 | Protease vaccine against heartworm |
Country Status (5)
Country | Link |
---|---|
EP (1) | EP0635058A1 (en) |
JP (1) | JPH07501219A (en) |
AU (1) | AU675214B2 (en) |
CA (1) | CA2123420A1 (en) |
WO (1) | WO1993010225A1 (en) |
Families Citing this family (14)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5795768A (en) * | 1991-02-12 | 1998-08-18 | Heska Corporation | Filariid nematode cysteine protease proteins, nucleic acid molecules and uses thereof |
US5639876A (en) * | 1991-02-12 | 1997-06-17 | Heska Corporation | Nucleic acid molecules encoding novel parasitic helminth proteins |
US5492695A (en) * | 1992-05-14 | 1996-02-20 | Colorado State University Research Foundation | Vaccinating cats against Dirofilaria immitis with an L4 homogenate |
US6623735B1 (en) * | 1992-10-21 | 2003-09-23 | John P. Dalton | Vaccine containing a thiol protease |
GB9403819D0 (en) * | 1994-02-28 | 1994-04-20 | Univ Leeds | Control of parasites |
AU702915B2 (en) * | 1994-05-26 | 1999-03-11 | Heska Corporation | Novel parasite protease genes and proteins |
US6265198B1 (en) | 1994-05-26 | 2001-07-24 | Heska Corporation | Parasite astacin metalloendopeptidase proteins |
AU726774B2 (en) * | 1994-05-26 | 2000-11-23 | Heska Corporation | Novel parasite protease genes and proteins |
US6281345B1 (en) | 1994-05-26 | 2001-08-28 | Heska Corporation | Parasite astacin metalloendopeptidase nucleic acid molecules and uses thereof |
DE19543554A1 (en) * | 1995-11-22 | 1997-05-28 | Bayer Ag | Identification of antigens from post-infectious nematodes for the development of new anthelmintics and vaccines |
FR2750865B1 (en) * | 1996-06-27 | 1998-12-04 | Rhone Merieux | RECOMBINANT LIVING VACCINE BASED ON CANINE HERPESVIRUS, IN PARTICULAR FOR SQUARE DISEASE, RABIES OR TYPE 2 PARAINFLUENZA VIRUS |
MXPA01010541A (en) * | 1999-04-21 | 2003-08-19 | Univ Georgia Res Found | Cysteine protease and inhibitors for prevention and treatment of neurocysticerocosis. |
US7416854B2 (en) * | 2004-01-22 | 2008-08-26 | Promega Corporation | Luminogenic and nonluminogenic multiplex assay |
US10485857B2 (en) | 2016-04-07 | 2019-11-26 | Boehringer Ingelheim Animal Health USA Inc. | Heartworm vaccine, methods and uses thereof |
Family Cites Families (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4761281A (en) * | 1986-04-22 | 1988-08-02 | Immunomed Corporation | Vaccine from Dirofilaria extracts |
US4842999A (en) * | 1986-08-11 | 1989-06-27 | Adi Diagnostics Inc. | Canine heartworm vaccine and diagnostic test |
EP0434909A3 (en) * | 1989-09-18 | 1992-08-19 | Synergen, Inc. | Anticoagulant and antihelminthic proteins and methods for the production and use of same |
WO1992013560A1 (en) * | 1991-02-12 | 1992-08-20 | Colorado State University Research Foundation | Reagents and methods for identification of vaccines |
-
1992
- 1992-11-12 CA CA002123420A patent/CA2123420A1/en not_active Abandoned
- 1992-11-12 AU AU30723/92A patent/AU675214B2/en not_active Expired
- 1992-11-12 EP EP92924400A patent/EP0635058A1/en not_active Withdrawn
- 1992-11-12 WO PCT/US1992/009702 patent/WO1993010225A1/en not_active Application Discontinuation
- 1992-11-12 JP JP5509382A patent/JPH07501219A/en not_active Ceased
Also Published As
Publication number | Publication date |
---|---|
WO1993010225A1 (en) | 1993-05-27 |
EP0635058A1 (en) | 1995-01-25 |
CA2123420A1 (en) | 1993-05-27 |
AU675214B2 (en) | 1997-01-30 |
EP0635058A4 (en) | 1994-12-07 |
JPH07501219A (en) | 1995-02-09 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AU675214B2 (en) | Protease vaccine against heartworm | |
US5686080A (en) | Parasitic helminth p4 proteins | |
AU705715B2 (en) | Use of flea proteases and protease inhibitors to protect animals from flea infestation | |
US5712143A (en) | Flea protease proteins, nucleic acid molecules, and uses thereof | |
EP0524834A2 (en) | Immunosuppressive drugs containing a cysteine protease | |
US6232096B1 (en) | Flea serine protease nucleic acid molecules and uses thereof | |
US5766609A (en) | Use of protease inhibitors and protease vaccines to protect animals from flea infestation | |
AU675443B2 (en) | Vaccines against metazoan parasites | |
JPH09510083A (en) | Nucleic acids encoding Der pIII, a household dust mite allergen, and uses thereof | |
US4788149A (en) | Proteolytic enzyme from blood-sucking nematodes and its uses as an anticoagulant as a vaccine and as an antithelminic agent | |
AU735717B2 (en) | Flea protease proteins, nucleic acid molecules, and uses thereof | |
AU2651695A (en) | Novel parasite protease genes and proteins | |
US5962257A (en) | Flea aminopeptidase nucleic acid molecules | |
US6177258B1 (en) | Flea protease proteins and uses thereof | |
US6214579B1 (en) | Flea leucine aminopeptidase nucleic acid molecules and uses thereof | |
US6936247B1 (en) | Filariid anti-P22U antibodies | |
US5972645A (en) | Flea serine protease nucleic acid molecules | |
US20030176382A1 (en) | Treatment of hookworm infection | |
AU726774B2 (en) | Novel parasite protease genes and proteins | |
US6204010B1 (en) | Flea protease proteins, nucleic acid molecules, and uses thereof | |
DK155887B (en) | METHOD FOR PREPARING OEB30-THR (R1) (R2) AA - INSULIN | |
JPH04305531A (en) | Method of administering therapeutic anticoagulant | |
PART | 11 Larval–Host Parasite Relationships | |
JPH07112999A (en) | Recombinant acarid allergen | |
WO2001074373A2 (en) | Hemoglobinase inhibitors and methods of use |